Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828719 | 0.88 | NPSR1 (0.36) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL1979013 | 0.86 | AR (0.40) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL29384188 | 0.85 | ALDH1A1 (0.37) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30939607 | 0.85 | SLC22A12 (0.36) | NPSR1KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL1980470 | 0.85 | SLC22A12 (0.36) | NPSR1KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL18952981 | 0.85 | BCAT2 (0.33) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL1981227 | 0.85 | ALDH1A1 (0.37) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL1981120 | 0.85 | CHRM2 (0.34) | ARNPSR1 | |
| SCHEMBL1980154 | 0.84 | IRAK4 (0.36) | ARNPSR1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30939598 | 0.83 | GPR119 (0.41) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | AR 4780/4885NPSR1 561/4885KDM4E 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.